Cite
HARVARD Citation
Garciaz, S. et al. (2019). Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC. Leukemia & lymphoma. 60 (11), pp. 2802-2805. [Online].